Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 3Colonic Neoplasms 3Sarcopenia 2Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Diarrhea 2Vaso-Occlusive Crises 1Stomach Neoplasms 1Seaweed Associated Changes in Healthy Subjects 1Rectal Neoplasms 1Proctitis 1Neoplasms 1Multiple Myeloma 1Mucositis 1Metabolic Syndrome 1Malnutrition 1Lymphoma 1Liver Failure 1Insulin Resistance 1Hyperandrogenism 1Head and Neck Neoplasms 1Glucose Intolerance 1Fibrosis 1Colonic Polyps 1Cholangiocarcinoma 1Chemotherapy-related Diarrhea 1Carcinoma, Hepatocellular 1Anovulation 1Anemia, Sickle Cell 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × maltodextrin × Clear all
NCT02819960 2022-12-14

Prevention of Irinotecan Induced Diarrhea by Probiotics

S&D Pharma SK s.r.o.

Phase 3 Completed
233 enrolled

Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡